Replimune Group Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Replimune Group has a total shareholder equity of $426.5M and total debt of $45.2M, which brings its debt-to-equity ratio to 10.6%. Its total assets and total liabilities are $535.0M and $108.5M respectively.
Anahtar bilgiler
10.6%
Borç/özkaynak oranı
US$45.19m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$469.12m |
| Eşitlik | US$426.45m |
| Toplam yükümlülükler | US$108.51m |
| Toplam varlıklar | US$534.97m |
Son finansal sağlık güncellemeleri
Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?
Aug 16
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Recent updates
Replimune: Strong Data In A Highly Differentiated Space
Sep 03Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?
Aug 16Replimune: Continuing To Justify The Bear Thesis (For Now)
May 22Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Replimune: In The 'Buy Zone' Again
Oct 01Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Sep 02Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business
May 24Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
Apr 30We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow
Feb 08Replimune Group EPS misses by $0.03
Feb 04Dosing underway in Replimune's early-stage cancer study with gene therapy
Jan 05Replimune: Interesting Developer Of Oncolytic Immunotherapies
Dec 06Replimune Group EPS misses by $0.02
Nov 05Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: REPL's short term assets ($480.3M) exceed its short term liabilities ($35.7M).
Uzun Vadeli Yükümlülükler: REPL's short term assets ($480.3M) exceed its long term liabilities ($72.8M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: REPL has more cash than its total debt.
Borcun Azaltılması: REPL's debt to equity ratio has increased from 0% to 10.6% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: REPL has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: REPL has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 31.3% each year.